Douglas JT - Search Results

1

Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu.

Bernal RM, Sharma S, Gardner BK, Douglas JT, Bergelson JM, Dubinett SM, Batra RK. Bernal RM, et al. Among authors: douglas jt. Clin Cancer Res. 2002 Jun;8(6):1915-23. Clin Cancer Res. 2002. PMID: 12060636

2

Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer.

Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D, Curiel DT. Miller CR, et al. Among authors: douglas jt. Cancer Res. 1998 Dec 15;58(24):5738-48. Cancer Res. 1998. PMID: 9865732

3

Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector.

Kasono K, Blackwell JL, Douglas JT, Dmitriev I, Strong TV, Reynolds P, Kropf DA, Carroll WR, Peters GE, Bucy RP, Curiel DT, Krasnykh V. Kasono K, et al. Among authors: douglas jt. Clin Cancer Res. 1999 Sep;5(9):2571-9. Clin Cancer Res. 1999. PMID: 10499635

4

Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity.

Krasnykh V, Dmitriev I, Navarro JG, Belousova N, Kashentseva E, Xiang J, Douglas JT, Curiel DT. Krasnykh V, et al. Among authors: douglas jt. Cancer Res. 2000 Dec 15;60(24):6784-7. Cancer Res. 2000. PMID: 11156365 Review.

5

Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.

Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piché A, Pierce GF, Alvarez RD, Siegal GP, Douglas JT, Curiel DT. Rancourt C, et al. Among authors: douglas jt. Clin Cancer Res. 1998 Oct;4(10):2455-61. Clin Cancer Res. 1998. PMID: 9796978

6

Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors.

Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Douglas JT, et al. Cancer Res. 2001 Feb 1;61(3):813-7. Cancer Res. 2001. PMID: 11221860

7

The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells.

Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT, Douglas JT. Kim M, et al. Among authors: douglas jt. Eur J Cancer. 2002 Sep;38(14):1917-26. doi: 10.1016/s0959-8049(02)00131-4. Eur J Cancer. 2002. PMID: 12204675

8

The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells.

Kim M, Sumerel LA, Belousova N, Lyons GR, Carey DE, Krasnykh V, Douglas JT. Kim M, et al. Among authors: douglas jt. Br J Cancer. 2003 May 6;88(9):1411-6. doi: 10.1038/sj.bjc.6600932. Br J Cancer. 2003. PMID: 12778071 Free PMC article.

9

Targeted adenoviral vectors.

Barnett BG, Crews CJ, Douglas JT. Barnett BG, et al. Among authors: douglas jt. Biochim Biophys Acta. 2002 May 3;1575(1-3):1-14. doi: 10.1016/s0167-4781(02)00249-x. Biochim Biophys Acta. 2002. PMID: 12020813 Review.

10

Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.

Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT. Tillman BW, et al. Among authors: douglas jt. Cancer Res. 2000 Oct 1;60(19):5456-63. Cancer Res. 2000. PMID: 11034088

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

176 results

Search Page

Filters